Gilead Sciences (GILD) Misses Q2 EPS by 31c; offers guidance

Gilead Sciences (NASDAQ: GILD) reported Q2 EPS of $1.34, $0.31 worse than the analyst estimate of $1.65. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $6.45 billion.

GUIDANCE:

Gilead Sciences sees FY2023 EPS of $6.45-$6.80, versus the consensus of $6.73. Gilead Sciences sees FY2023 revenue of $26.3-26.7 billion, versus the consensus of $26.663 billion.

For earnings history and earnings-related data on Gilead Sciences (GILD) click here.

You May Also Be Interested In

• Octave Intelligence plc (OCTV) Tops Q2 EPS by 4c ; Offers Guidance
• Riskified Ltd. (RSKD) Reports In-Line Q2 EPS ; Offers Guidance
• Humacyte, Inc. (HUMA) Misses Q2 EPS by 7c